Mehta TI, Weissman S, Fung BM, Tabibian JH. Geoepidemiologic variation in outcomes of primary sclerosing cholangitis. World J Hepatol 2020; 12(4): 116-124 [PMID: 32685104 DOI: 10.4254/wjh.v12.i4.116]
Corresponding Author of This Article
James H Tabibian, MD, PhD, FACP, Department of Medicine, UCLA-Olive View Medical Center, 14445 Olive View Dr 2B-182, Sylmar, CA 91342, United States. jtabibian@dhs.lacounty.gov
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Hepatol. Apr 27, 2020; 12(4): 116-124 Published online Apr 27, 2020. doi: 10.4254/wjh.v12.i4.116
Geoepidemiologic variation in outcomes of primary sclerosing cholangitis
Tej I Mehta, Simcha Weissman, Brian M Fung, James H Tabibian
Tej I Mehta, Department of Medicine, University of South Dakota Sanford School of Medicine, Sioux Falls, SD 57108, United States
Simcha Weissman, Department of Medicine, Hackensack University-Palisades Medical Center, North Bergen, NJ 07047, United States
Brian M Fung, Department of Medicine, Olive View-UCLA Medical Center, Sylmar, CA 91342, United States
James H Tabibian, Department of Medicine, UCLA-Olive View Medical Center, Sylmar, CA 91342, and Health Sciences Clinical Associate Professor, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, United States
Author contributions: Weissman S and Mehta TI assisted with data acquisition, analyses, and manuscript preparation; Weissman S, Mehta TI and Tabibian JH drafted and critically revised the manuscript; Fung BM critically revised the manuscript and provided input regarding methodology; Tabibian JH provided direct supervision and guidance; Weissman S and Tabibian JH are the article guarantors; all authors agree to the final version of this manuscript.
Conflict-of-interest statement: Authors declare no conflict of interests for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: James H Tabibian, MD, PhD, FACP, Department of Medicine, UCLA-Olive View Medical Center, 14445 Olive View Dr 2B-182, Sylmar, CA 91342, United States. jtabibian@dhs.lacounty.gov
Received: February 19, 2020 Peer-review started: February 19, 2020 First decision: March 15, 2020 Revised: March 15, 2020 Accepted: March 24, 2020 Article in press: March 24, 2020 Published online: April 27, 2020 Processing time: 63 Days and 21.3 Hours
Core Tip
Core tip: There appears to be considerable geoepidemiologic variation in the outcomes of primary sclerosing cholangitis (PSC). Median liver transplantation-free survival in adults with PSC ranges from 14 to 21 years, depending on geographic region. Post-liver transplantation survival for PSC in North America and Europe appears to be nearly twice that found in Asia. The overall average risk of cholangiocarcinoma among patients with PSC is approximately 400 times that of the general population, occurring in roughly 7%-9% of all patients with PSC. However, these rates vary from region to region, with East Asia having rates roughly three-times higher compared to other regions. Studies from North America, Europe, and Oceania generally report worse clinical outcomes for patients with PSC-inflammatory bowel disease compared to patients with only PSC or inflammatory bowel disease; however, this association is less prominent in studies from Asia.
